1. Home
  2. ATXS vs ALT Comparison

ATXS vs ALT Comparison

Compare ATXS & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATXS
  • ALT
  • Stock Information
  • Founded
  • ATXS 2008
  • ALT 1997
  • Country
  • ATXS United States
  • ALT United States
  • Employees
  • ATXS N/A
  • ALT N/A
  • Industry
  • ATXS Biotechnology: Pharmaceutical Preparations
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • ATXS Health Care
  • ALT Health Care
  • Exchange
  • ATXS Nasdaq
  • ALT Nasdaq
  • Market Cap
  • ATXS 401.2M
  • ALT 472.3M
  • IPO Year
  • ATXS 2015
  • ALT N/A
  • Fundamental
  • Price
  • ATXS $4.48
  • ALT $5.80
  • Analyst Decision
  • ATXS Strong Buy
  • ALT Strong Buy
  • Analyst Count
  • ATXS 6
  • ALT 7
  • Target Price
  • ATXS $30.00
  • ALT $21.00
  • AVG Volume (30 Days)
  • ATXS 501.6K
  • ALT 2.0M
  • Earning Date
  • ATXS 05-20-2025
  • ALT 05-13-2025
  • Dividend Yield
  • ATXS N/A
  • ALT N/A
  • EPS Growth
  • ATXS N/A
  • ALT N/A
  • EPS
  • ATXS N/A
  • ALT N/A
  • Revenue
  • ATXS N/A
  • ALT $20,000.00
  • Revenue This Year
  • ATXS N/A
  • ALT N/A
  • Revenue Next Year
  • ATXS N/A
  • ALT N/A
  • P/E Ratio
  • ATXS N/A
  • ALT N/A
  • Revenue Growth
  • ATXS N/A
  • ALT N/A
  • 52 Week Low
  • ATXS $3.56
  • ALT $3.55
  • 52 Week High
  • ATXS $12.92
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • ATXS 38.86
  • ALT 60.47
  • Support Level
  • ATXS $4.25
  • ALT $4.95
  • Resistance Level
  • ATXS $5.47
  • ALT $6.05
  • Average True Range (ATR)
  • ATXS 0.35
  • ALT 0.37
  • MACD
  • ATXS 0.01
  • ALT 0.11
  • Stochastic Oscillator
  • ATXS 27.45
  • ALT 85.17

About ATXS Astria Therapeutics Inc.

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

About ALT Altimmune Inc.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Share on Social Networks: